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Massively Parallel Sequencing (MPS) allows sequencing
of entire exomes and genomes to now be done at rea-
sonable cost, and its utility for identifying genes respon-
sible for rare Mendelian disorders has been
demonstrated. However, for a complex disease such as
the common cancers, study designs need to accommo-
date substantial degrees of locus, allelic, and phenotypic
heterogeneity, as well as complex relationships between
genotype and phenotype. Such considerations include
careful selection of samples for sequencing and a well-
developed strategy for identifying the few “true” disease
susceptibility genes from among the many irrelevant
g e n e st h a tw i l lb ef o u n dt oh a r b o rr a r ev a r i a n t s .T o
examine these issues we have performed simulation-
based analyses in order to compare several strategies for
MPS sequencing in complex disease. Factors examined
include genetic architecture, sample size, number and
relationship of individuals selected for sequencing, and a
variety of filters based on variant type, multiple observa-
tions of genes and concordance of genetic variants
within pedigrees. A two-stage design was assumed
where genes from the MPS analysis of high-risk families
are evaluated in a secondary screening phase of a larger
set of probands with more modest family histories.
Designs were evaluated using a cost function that
assumed the cost of sequencing the whole exome was
400 times that of sequencing a single candidate gene.
Results indicate that while requiring variants to be iden-
tified in multiple pedigrees and/or in multiple indivi-
duals in the same pedigree are effective strategies for
reducing false positives, there is a danger of over-filter-
ing so that most true susceptibility genes are missed. In
most cases, sequencing more than two individuals per
pedigree results in reduced power without any benefit in
terms of reduced overall cost. Further, our results sug-
gest that although no single strategy is optimal, simula-
tions can provide important guidelines for study design.
Examples in familial breast cancer and melanoma will
be presented to illustrate these points.
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